ArticleCancers2012
Tumor-associated antigens for specific immunotherapy of prostate cancer.
Article in Cancers, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- A meta-analysis of epitopes in prostate-specific antigens identifies opportunities and knowledge gaps.Human immunology · 2023Pooled it
- Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next.NPJ vaccines · 2026Review
- Comprehensive Biochemical Insights into Prostate-Specific Antigen: From Biomarker to Functional Mediator in Prostate Cancer Pathophysiology.Anti-cancer agents in medicinal chemistry · 2026Review
- Engineering spherical nucleic acids for precision cancer therapy: design strategies and medical applications.Theranostics · 2026Review
- Advancing CAR-T therapy in prostate cancer: overcoming the tumor microenvironment and enhancing efficacy.Frontiers in oncology · 2026Review
- Immunotherapy in metastatic prostate cancer.Therapeutic advances in medical oncology · 2025Review
- T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.Cancer biology & therapy · 2024Review
- Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.Prostate cancer and prostatic diseases · 2024Article
- Preclinical Characterization of theInternational journal of molecular sciences · 2023Article
- First in man study: Bcl-Xl_42-CAFFrontiers in immunology · 2023Article
- Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.Stem cell research & therapy · 2022Review
- Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T Cells.International journal of molecular sciences · 2022Article
- Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management.Cancers · 2022Article
- Review
- The potential of CAR T cell therapy for prostate cancer.Nature reviews. Urology · 2021Review
- Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.Journal for immunotherapy of cancer · 2021Article
- TGM4: an immunogenic prostate-restricted antigen.Journal for immunotherapy of cancer · 2021Article
- Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.Cancers · 2021Review
- Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review.International journal of molecular sciences · 2021Review
- Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.Cancer immunology, immunotherapy : CII · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is the most common noncutaneous cancer diagnosis and the second leading cause of cancer-related deaths among men in the United States. Effective treatment modalities for advanced metastatic PCa are limited. Immunotherapeutic strategies based on T cells and antibodies represent interesting approaches to prevent progression from localized to advanced PCa and to improve survival outcomes for patients with advanced disease. CD8+ cytotoxic T lymphocytes (CTLs) efficiently recognize and destroy tumor cells. CD4+ T cells augment the antigen-presenting capacity of dendritic cells and promote the expansion of tumor-reactive CTLs. Antibodies mediate their antitumor effects via antibody-dependent cellular cytotoxicity, activation of the complement system, improving the uptake of coated tumor cells by phagocytes, and the functional interference of biological pathways essential for tumor growth. Consequently, several tumor-associated antigens (TAAs) have been identified that represent promising targets for T cell- or antibody-based immunotherapy. These TAAs comprise proteins preferentially expressed in normal and malignant prostate tissues and molecules which are not predominantly restricted to the prostate, but are overexpressed in various tumor entities including PCa. Clinical trials provide evidence that specific immunotherapeutic strategies using such TAAs represent safe and feasible concepts for the induction of immunological and clinical responses in PCa patients. However, further improvement of the current approaches is required which may be achieved by combining T cell- and/or antibody-based strategies with radio-, hormone-, chemo- or antiangiogenic therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.